Rhythm Biosciences Secures Supply Deal With UK Cancer Diagnostics Company

MT Newswires Live
03/04

Rhythm Biosciences (ASX:RHY) secured an agreement with UK-incorporated cancer diagnostics company Digistain for the supply of its geneType genetic test portfolio, according to a Wednesday filing with the Australian bourse.

The deal grants Digistain the right to market and distribute the genetic test portfolio in Southeast Asia for an initial 12-month term, with renewal provisions supporting scalable expansion, the filing said.

Revenue is generated per test as samples are processed and reported, with invoicing done monthly and 30-day payment terms, per the filing.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10